Biotaspheric provides focused expertise, resources and investment to accelerate innovative technology development in antimicrobial resistance.

Biotaspheric’s industry-experienced team draws upon a network of advisors, collaborators and investors to identify and select innovative technologies, while providing a tailored range of services to accelerate product development and help combat the antimicrobial resistance crisis and improve patient care.

About Us

The threat of antimicrobial resistance (AMR), rendering current antibiotics, antifungals and antivirals obsolete is an urgent global issue.

Biotaspheric recognises the urgency and necessity for new innovative anti-infective technologies and is at the forefront of the changing commercial proposition for AMR and the evolving regulatory market. Biotaspheric can identify promising technologies and accelerate innovative anti-infectives via their unique offering:

  • Expertise

    The Biotaspheric team comprises global specialists across each key area of development, from investment, pre-clinical and clinical development, through to market access and reimbursement, providing a breadth of robust support and knowledge

  • Knowledge

    Our team of experts understands the nuances of the anti-infective market. With decades of academic and industry experience, we can identify the optimum indications for development and provide guidance on product life cycle management and responsible use of new treatments, helping to limit further resistance development.

  • Network

    Biotaspheric offers a holistic approach to development through our network of recognised alliances across the industry.

  • Investment

    Biotaspheric’s unique combination of network, knowledge and expertise helps to secure funding and investment for product development

Background - AMR

Antibiotics have been the cornerstone of modern medicine, enabling us to treat infections and underpinning successful medical procedures for decades. Now, global public health is under threat with the emergence of antimicrobial resistance (AMR) – the ability of bacteria, parasites, viruses and fungi to resist treatments.

  • AMR not only hinders our ability to treat common place infections, it also affects integral medical procedures (e.g. surgery) and the efficacy of other complex therapies such as chemotherapy and diabetes management
  • Currently AMR is causing 700,000 deaths annually, which is set to increase: the World Health Organisation predicts 10 million deaths from antibiotic resistance by 2050 unless new and innovative antibiotics are developed

Antibiotic development is no longer a priority area for the pharmaceutical industry, with many companies exiting R&D altogether. However, there are an increasing number of products with new mechanisms of action in development by innovators that are urgently needed to combat AMR.

Biotaspheric provides the full range of expertise and resources to accelerate the development of novel anti-infective technologies. We believe the high unmet need and changing regulatory and access landscape can pave the way for successful product commercialisation and improvement in patient care.

Our Approach

For Product Innovators

The spectrum of services Biotaspheric offers is tailored to the distinct requirements of each innovative product to enhance its development. Our services are uniquely adaptable depending on the requirements of the technology and the market and include:

  • Co-development of experts who have renowned industry knowledge and accomplishment in developing successful antimicrobial products and understand the complexities of anti-infectives development
  • Collaboration with leading industry third party vendors (CRO, Microbiology laboratory, manufacturers) to ensure that novel technologies are successfully developed to the highest quality and with greatest efficiency
  • Consultancy, Biotaspheric can seek and find appropriate investments in products, from a range of sources and couples the funding with expert knowledge to accelerate innovative technology development

For Investors

Biotaspheric provides opportunities for investors from a variety of sources with an analysed and curated portfolio of innovative anti-infective technology that, coupled with Biotaspheric expert network, knowledge and understanding of the industry, ensures investors have the opportunity to invest in a breadth of ground-breaking technologies that have the highest potential for successful commercialisation. Biotaspheric offers:

  • Carefully selected novel anti-infective technologies using stringent assessment criteria, including artificial intelligence and expert panels, which helps to ensure that risks are minimised, and projects have a greater chance of progressing along the development life-cycle.
  • An objective approach, with a broad range of innovative technologies across drug classes, mechanisms of actions and indications, while ensuring that each technology is given individual commitment, expertise, knowledge and investment
  • An expert team which recognises the shifting regulatory landscape of anti-infectives and life threatening unmet medical need, paired with a structured multiple-step analysis, to guarantee the technologies have the most suitable development plan in the most appropriate indications

To find out more email enquires@biotaspheric.com

People

Andrew Copestake Ph.d,

CBDO

Border circle BIO
Kevin Cox,

Executive Chair / CEO

Border circle BIO
Dr Anthony Lockett,

CMO

Border circle BIO
Elizabeth Lockett MBA

Company Secretary

Border circle BIO
Eleanor Neilson,

PM

Border circle BIO
Tim Pedley,

CFO

Border circle BIO
Klemens Schütte,

COO

Border circle BIO

Andrew Copestake, Ph.d

CBDO

Entrepreneurial and commercially focused, Andrew is a senior executive with over 25 years’ experience in the pharmaceutical, biotechnology and CRO industries. He has held positions across the sector at all levels from academic researcher to Chief Executive and has gained significant international experience, from working in Global positions and at a European level. Andrew has held numerous board-level positions with successful engagement and fund raising.

Andrew is an expert in pharmaceutical commercial and business development, his experience spans across disciplines including commercial development and partnering, with a particular focus on creating and executing successful licensing deals. Andrew is a Fellow of the Royal Society of Medicine.

Kevin Cox,

Executive Chair / CEO

Kevin has over 25 years’ experience in the life science industry, covering a wide range of sectors such as biomanufacturing, anti-infectives development, biomedical imaging, pathology, and clinical pharmacology. Serving as CEO of high growth biotechnology businesses, he has extensive experience in strategy, corporate development, M&A, financing and joint ventures. With a passion for improving translational science, Kevin has developed strong links to government, funding bodies and academia, and has contributed to a number of public sector advisory committees. Kevin currently has non-executive roles with Biorelate Limited, Syndermix SA and the British Neuroscience Association

Dr Anthony Lockett

CMO

Tony is an expert in the development and commercialisation of anti-infective products. He has over 30 years’ experience in the biopharmaceutical, drug delivery, medical devices and diagnostics industry, which spans multinational corporations, CRO’s AIM listed companies, start- up companies and the charity sector both in the EU and America. In these settings he has held several roles including board member, CMO and scientific advisor. His previous experience in anti-infective work comprises of lifecycle management, strategic development and sourcing investment. His experience in successfully securing funding, includes receiving grant funding and raising in excess of $100 million to fund development programmes for vaccines, anti-virals, medical diagnostics and biomarkers. Tony is a global fellow in medicines development at IFAPP (International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine) and an academic at Kings College London.

Elizabeth Lockett MBA,

Company Secretary

Elizabeth has over 15 years in successful management of Life Science businesses. Her experience spans from the daily operational management; communications; medical regulation; research to strategic involvement on progression on projects and investment requirements. She is currently serving as director and co-owner of MEDQP Ltd. and Information Change Organisation Ltd, specialist companies in the development of pharmaceutical products and change management respectively.

Elizabeth has continued to maintain her skills and expertise in relevant business management requirements and is currently a member of the Small Business Federation. Prior to working in Life Science business sector Elizabeth worked as a cancer nurse for the National Health Service.

Eleanor Neilson,

PM

Eleanor has worked for the last seven years in the pharmaceutical industry across a breadth of specialities. Starting as a research technician at one of Europe’s largest early-phase Clinical Research Organisations, before working in pharmaceutical consulting, specialising in pharmaceutical product pricing and market access. She became a specialist in EU5 reimbursement and product evaluations, working on a range of projects including innovative therapies, biosimilars, medical devices and companion diagnostics. Most recently she has worked in Healthcare Communications, across a range of disease areas and accounts including, consumer healthcare product launches, disease awareness campaigns, patient advocacy and healthcare policy.

Eleanor is fully trained and qualified in PRINCE2 project management at Foundation and Practitioner level.

Tim Pedley,

CFO

Tim is a Chartered Accountant with almost 20 years’ experience working in leading finance positions across a variety of companies and sectors, ranging from small companies to large PLCs but now focuses on media and technology SME sector. Tim provides expertise in the full suite of accounting services including establishing accounting systems, building company-specific management reporting including setting up KPIs and key management matrices and overseeing the budgeting process. Key achievements include successfully securing equity and working capital financing of £29m from a variety of sources, including grants. Tim has an in-depth understanding of commercial law through his Master’s degree he obtained from Manchester University, which allows him to provide practical legal management in addition to the full suite of financial services. Currently, Tim provides a range of financial consultancy services through his consulting company.

Klemens Schütte,

COO

Klemens is a seasoned industry professional, with 30 years of experience in Clinical Development, combined with commercial experience within BioPharma and in depth understanding of CRO companies. He has a German and US University background in Biology and Biochemistry which has allowed him to excel in the biopharmaceutical industry. Following his role as Head of Operations at ASTA Medica, he has held numerous executive positions and Board memberships, including working for more than 10 years at the Global Clinical Development Company - Ergomed plc serving mainly as COO, followed by over 3 years as the CEO of Global CRO, Ecron Acunova. Currently, he is serving as CEO of Talentmark Deutschland GmbH and Executive Board Director of the Talentmark Group.